- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
New York University
Headquarters: New York, NY, United States
Website: http://www.nyu.edu
Year Founded: 1832
Status: Non-biopharma
Biopharma related deals can be found by searching the organization's name in the Deals Module.
BioCentury | Apr 1, 2025
Distillery Therapeutics
Inhibiting CNDP2 to disrupt nutrient cooperativity in cancer
BioCentury | Mar 26, 2025
Discovery & Translation
Science Spotlight: New insight into LAG3’s checkpoint function
BioCentury’s roundup of translational innovations also includes a blood-based T cell assay for T1D, a degrader using a new E3 ligase, and papers from newcos
BioCentury | Sep 3, 2024
Discovery & Translation
Eyes on the target: Drug discovery’s new paradigm
Back to School 2024: Can biotech write a more successful playbook for translating from target to product?
BioCentury | Aug 30, 2024
Discovery & Translation
Science Spotlight: Roche’s intestinal immuno-organoids, cytokine METRNL’s role in tumors, and more
BioCentury’s roundup of translational innovations
BioCentury | Jul 13, 2024
Management Tracks
CEO moving on from Theolytics
Plus: CSO Luis Borges departs Metagenomi, and updates from Diadem and CureLab
BioCentury | Mar 8, 2024
Discovery & Translation
Distillery spotlight: new ubiquitin-modulating mechanisms from academia
Innovators are finding new ways of targeting E3 ligases and DUBs in liver diseases and cancer: BioCentury’s survey of the 2023 translational literature
BioCentury | Feb 5, 2024
Guest Commentary
The elliptical billiard balls of FDA policy
Chevron deference has, in essence, rigged the game for FDA. Now more than ever, the agency needs modernized, defensible policies
BioCentury | Nov 3, 2023
Discovery & Translation
Dimeric IgA targets intracellular oncogenes; plus taRNAs and more
BioCentury’s roundup of translational innovations
Items per page:
1 - 10 of 396